Impact of erythropoietin on arterial hypertension
Keywords:
arterial hypertension, atherosclerosis, diseases constitute, entirety health, immunosuppressive diseasesAbstract
Cardiovascular and renal diseases constitute two pathophysiological contexts of progressive fatal recognitions worldwide and as priorities in terms of health in its entirety. Erythropoietin is a glycoprotein hormone which produces red blood cells, which carry oxygen in the blood. The objective was to know the most prevalent modifiable risk factors found in arterial hypertension, since this disease is the third cause of death in the world, the bibliographic search and the inductive-deductive method were used. The result was that treatment with recombinant human erythropoietin-stimulating agents is considered effective in improving the management of anemia associated with chronic kidney disease, since it has cardioprotective, renoprotective and neuroprotective functions.
Downloads
References
Brar, S. K., Perveen, S., Chaudhry, M. R., AlBabtain, S., Amreen, S., & Khan, S. (2021). Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity. Cureus, 13(1).
BTA. (2020). Tratamiento de la hipertensión arterial:nuevas guías. Boletín terapeutico Andaluz, 4(35). doi:10.11119/BTA2020-35-04
Chiong, J. R., Aronow, W. S., Khan, I. A., Nair, C. K., Vijayaraghavan, K., Dart, R. A., ... & Geraci, S. A. (2008). Secondary hypertension: current diagnosis and treatment. International journal of cardiology, 124(1), 6-21. https://doi.org/10.1016/j.ijcard.2007.01.119
Esforzado, N., Cases, A., & Bono, M. (1999). Efecto del tratamiento con eritropoyetina sobre la actividad del sistema nervioso simpático y los receptores α2 en pacientes IRCT hemodializados. Nefrologia, XIX(1). Http://Revistanefrología.com
Gómez, J., Camacho, P., & López, P. (2019). Control y tratamiento de la hipertensión arterial: Programa 20-20. Revista Colombiana de Cardiología, 26(2). doi:10.1016/j.rccar.2018.06.008
Gradman, A. H., Basile, J. N., Carter, B. L., Bakris, G. L., & American Society of Hypertension Writing Group. (2010). Combination therapy in hypertension. Journal of the American Society of Hypertension, 4(2), 90-98. https://doi.org/10.1016/j.jash.2010.03.001
Katavetin, P., Tungsanga, K., Eiam-Ong, S., & Nangaku, M. (2007). Antioxidative effects of erythropoietin. Kidney International, 72, S10-S15. https://doi.org/10.1038/sj.ki.5002482
Kaufner, L., von Heymann, C., Henkelmann, A., Pace, N. L., Weibel, S., Kranke, P., ... & Gill, R. (2020). Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non‐cardiac surgery. Cochrane Database of Systematic Reviews, (8).
Kumar, J. (2013). Epidemiology of hypertension. Clinical Queries: Nephrology, 2(2), 56-61. https://doi.org/10.1016/j.cqn.2013.04.005
Maiese, K., Li, F., & Chong, Z. Z. (2004). Erythropoietin in the brain: can the promise to protect be fulfilled?. Trends in pharmacological sciences, 25(11), 577-583. https://doi.org/10.1016/j.tips.2004.09.006
Nekoui, A., & Blaise, G. (2017). Erythropoietin and nonhematopoietic effects. The American journal of the medical sciences, 353(1), 76-81. https://doi.org/10.1016/j.amjms.2016.10.009
Ozkurt, M., Uzuner, K., Erkasap, N., Kus, G., Ozyurt, R., Uysal, O., ... & Kutlay, O. (2018). Erythropoietin protects the kidney by regulating the effect of TNF-α in L-NAME-induced hypertensive rats. Kidney and Blood Pressure Research, 43(3), 807-819.
Rodrigues-Diez, RR, Tejera-Muñoz, A., Orejudo, M., Marquez-Exposito, L., Santos, L., Rayego-Mateos, S., ... & Ruiz-Ortega, M. (2021). Interleukin-17A: possible mediator and therapeutic target in hypertension. Nephrology , 41 (3), 244-257. https://doi.org/10.1016/j.nefro.2020.11.009
SEQCML. (2021). Eritropoyetina. Lab tests online. https://labtestsonline.es/tests/eritropoyetina
Staessen, J. A., Wang, J., Bianchi, G., & Birkenhäger, W. H. (2003). Essential hypertension. The Lancet, 361(9369), 1629-1641. https://doi.org/10.1016/S0140-6736(03)13302-8
Takagi, H., Watanabe, D., Suzuma, K., Kurimoto, M., Suzuma, I., Ohashi, H., ... & Murakami, T. (2007). Novel role of erythropoietin in proliferative diabetic retinopathy. Diabetes Research and Clinical Practice, 77(3), S62-S64. https://doi.org/10.1016/j.diabres.2007.01.035
Tanaka, T., & Eckardt, K. U. (2018). HIF activation against CVD in CKD: novel treatment opportunities. In Seminars in nephrology (Vol. 38, No. 3, pp. 267-276). WB Saunders. https://doi.org/10.1016/j.semnephrol.2018.02.006
Vittori, D., Chamorro, M. E., & Nesse, A. (2016). Erythropoietic and non-erythropoietic functions of erythropoietin: Therapeutic considerations. Acta Bioquimica Clinica Latinoamericana, 50(4), 773-782.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
